Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 100/100

Termination Rate

25.0%

1 terminated out of 4 trials

Success Rate

0.0%

-86.5% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

0

Data Visualizations

Phase Distribution

4Total
P 1 (1)
P 2 (3)

Trial Status

Withdrawn1
Not Yet Recruiting1
Terminated1
Suspended1

Clinical Trials (4)

Showing 4 of 4 trials
NCT05960773Phase 2Suspended

Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma

NCT06654050Phase 2Withdrawn

Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma

NCT07282873Phase 1Not Yet Recruiting

Study of TYK-01054 Capsules in Patients With Advanced Solid Tumors

NCT05563272Phase 2Terminated

89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors

Showing all 4 trials

Research Network

Activity Timeline